Actualización en Bacteriemia por Staphylococcus Aureus
Barra lateral del artículo
Descargas
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Contenido principal del artículo
Resumen
El Staphylococcus aureus es un patógeno bacteriano de distribución mundial y es el principal responsable de las bacteriemias en numerosas áreas geográficas. Las tasas de resistencia a antibióticos han aumentado exponencialmente y diversos estudios han demostrado que las cepas resistentes ya no se limitan al ámbito hospitalario, con un aumento significativo de las infecciones adquiridas en la comunidad por bacterias meticilino-resistentes. La epidemiología de la infección es cambiante, lo que ha dificultado el enfoque inicial de los pacientes con bacteriemia por S. aureus, sumado a la cantidad de antibióticos relativamente limitada para su tratamiento. A pesar de los avances médicos y científicos, la mortalidad atribuible a esta infección ha permanecido estable durante los últimos años, por lo que se ha convertido en un problema para los sistemas de salud con un aumento considerable en los costos de atención. Es necesario realizar una actualización en este tópico para facilitar un tratamiento clínico adecuado de las bacteriemias por S. aureus.
Citas
David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010; 23(3):616-687.
Chaves F, García-Martínez J, de Miguel S, Sanz F, Otero JR. Epidemiology and clonality of methicillin-resistant and methicillin-susceptible Staphylococcus aureus causing bacteremia in a tertiary-care hospital in Spain. Infect Control Hosp Epidemiol. 2005; 26(2):150-156.
Corey GR. Staphylococcus aureus bloodstream infections: definitions and treatment. Clin Infect Dis. 2009; 48 Suppl 4: S254-259.
Jiménez JN, Ocampo AM, Vanegas JM, Rodriguez EA, Mediavilla JR, Chen L, et al. A comparison of methicillin-resistant and methicillin-susceptible Staphylococcus aureus reveals no clinical and epidemiological but molecular differences. Int J Med Microbiol. 2013; 303(2):76-83.
Naber CK, Baddour LM, Giamarellos-Bourboulis EJ, Gould IM, Herrmann M, Hoen B, et al. Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin Infect Dis. 2009; 48 Suppl 4: S260-270.
Del Rio A, Cervera C, Moreno A, Moreillon P, Miró JM. Patients at risk of complications of Staphylococcus aureus bloodstream infection. Clin Infect Dis. 2009; 48 Suppl 4: S246-253.
Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Török ME, et al. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis. 2011; 11(3):208-222.
Rehm SJ, Tice A. Staphylococcus aureus: Methicillin-susceptible S. aureus to methicillin-resistant S. aureus and vancomycin-resistant S. aureus. Clin Infect Dis. 2010; 51 Suppl 2: S176-182.
Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of communityacquired infections. Ann Intern Med. 2002; 137(10):791-197.
Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH. Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit Care Med. 2006; 34(10):2588- 2595.
Siegman-Igra Y, Fourer B, Orni-Wasserlauf R, Golan Y, Noy A, Schwartz D, et al. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis. 2002; 34(11):1431-1439.
Van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012; 25(2):362-386.
Tacconelli E, Venkataraman L, de Girolami PC, DAgata EMC. Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: distinguishing between communityacquired versus healthcare-associated strains. J Antimicrob Chemother. 2004; 53(3):474-479.
Cervera C, Almela M, Martínez-Martínez JA, Moreno A, Miró JM. Risk factors and management of Gram-positive bacteraemia. Int J Antimicrob Agents. 2009; 34 Suppl 4: S26-30.
Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother. 2005; 56(5):923-929.
Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003; 36(11):1418-1423.
Naves KSC, Vaz da Trindade N, Gontijo Filho PP. Methicillin-resistant Staphylococcus aureus bloodstream infection: risk factors and clinical outcome in non-intensive-care units. Rev Soc Bras Med Trop. 2012; 45(2):189-193.
Saginur R, Suh KN. Staphylococcus aureus bacteraemia of unknown primary source: where do we stand? Int J Antimicrob Agents. 2008; 32 Suppl 1: S21-25.
Paul M, Kariv G, Goldberg E, Raskin M, Shaked H, Hazzan R, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2010; 65(12):2658-65.
Naber CK. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis. 2009; 48 Suppl 4: S231-237.
Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis. 2008; 198(3):336-343.
Melzer M, Eykyn SJ, Gransden WR, Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis. 2003; 37(11):1453-1460.
Wang J-L, Chen S-Y, Wang J-T, Wu GH-M, Chiang W-C, Hsueh P-R, et al. Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus. Clin Infect Dis. 2008; 46(6):799-806.
Park SY, Park K-H, Bang KM, Chong YP, Kim S-H, Lee S-O, et al. Clinical significance and outcome of polymicrobial Staphylococcus aureus bacteremia. J Infect. 2012; 65(2):119-127.
Pien BC, Sundaram P, Raoof N, Costa SF, Mirrett S, Woods CW, et al. The clinical and prognostic importance of positive blood cultures in adults. Am J Med. 2010; 123(9):819-828
Asgeirsson H, Kristjansson M, Kristinsson KG, Gudlaugsson O. Staphylococcus aureus bacteraemia- -Nationwide assessment of treatment adequacy and outcome. J Infect. 2011; 62(5):339-346.
Shime N, Kosaka T, Fujita N. The importance of a judicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis. 2010; 29(12):1475-1479.
Burkey MD, Wilson LE, Moore RD, Lucas GM, Francis J, Gebo KA. The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era. HIV Med. 2008; 9(10):858-862.
Aygen B, Yörük A, Yýldýz O, Alp E, Kocagöz S, Sümerkan B, et al. Bloodstream infections caused by Staphylococcus aureus in a university hospital in Turkey: clinical and molecular epidemiology of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2004; 10(4):309-314.
Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003; 36(1):53-59.
McClelland RS, Fowler VG Jr, Sanders LL, Gottlieb G, Kong LK, Sexton DJ, et al. Staphylococcus aureus bacteremia among elderly vs younger adult patients: comparison of clinical features and mortality. Arch Intern Med. 1999; 159(11):1244-1247.
Ponce-de-León A, Camacho-Ortiz A, Macías AE, Landín-Larios C, Villanueva-Walbey C, TrinidadGuerrero D, et al. Epidemiology and clinical characteristics of Staphylococcus aureus bloodstream infections in a tertiary-care center in Mexico City: 2003-2007. Rev Invest Clin. 2010; 62(6):553-559.
Blyth CC, Darragh H, Whelan A, O’Shea JP, Beaman MH, McCarthy JS. Evaluation of clinical guidelines for the management of Staphylococcus aureus bacteraemia. Intern Med J. 2002; 32(5-6):224-232.
Wolkewitz M, Frank U, Philips G, Schumacher M, Davey P, BURDEN Study Group. Mortality associated with in-hospital bacteraemia caused by Staphylococcus aureus: a multistate analysis with follow-up beyond hospital discharge. J Antimicrob Chemother. 2011; 66(2):381-386.
Ladhani S, Konana OS, Mwarumba S, English MC. Bacteraemia due to Staphylococcus aureus. Arch Dis Child. 2004; 89(6):568-571.
Cabell CH, Fowler VG Jr. Importance of aggressive evaluation in patients with Staphylococcus aureus bacteremia. Am Heart J. 2004; 147(3):379-380.
Molina FJ, Díaz CA, Barrera L, de la Rosa G, Dennis R, Dueñas C, et al. [Microbiological profile of infections in the Intensive Care Units of Colombia (EPISEPSIS Colombia]. Med Intensiva. 2011; 35(2):75-83.
Rodríguez-Noriega E, Seas C, Guzmán-Blanco M, Mejía C, Alvarez C, Bavestrello L, et al. Evolution of methicillin-resistant Staphylococcus aureus clones in Latin America. Int J Infect Dis. 2010; 14(7):e560-566.
Garza-González E, Dowzicky MJ. Changes in Staphylococcus aureus susceptibility across Latin America between 2004 and 2010. Braz J Infect Dis. 2013; 17(1):13-19.
Mejía C, Zurita J, Guzmán-Blanco M. Epidemiology and surveillance of methicillin-resistant Staphylococcus aureus in Latin America. Braz J Infect Dis. 2010; 14 Suppl 2: S79-86.
Reyes J, Rincon S, Diaz L, Panesso D, Contreras GA, Zurita J, et al. Dissemination of MethicillinResistant Staphylococcus aureus (MRSA), USA300 Sequence Type 8 Lineage in Latin-America. Clin Infect Dis. 2009; 49(12):1861-1867.
Gales AC, Jones RN, Andrade SS, Pereira AS, Sader HS. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. Braz J Infect Dis. 2005; 9(5):348-356.
Espinosa CJ, Cortés JA, Castillo JS, Leal AL. [Systematic review of antimicrobial resistance among Gram positive cocci in hospitals in Colombia]. Biomedica. 2011; 31(1):27-34.
Arias CA, Rincon S, Chowdhury S, Martínez E, Coronell W, Reyes J, et al. MRSA USA300 clone and VREF--a U.S.-Colombian connection? N Engl J Med. 2008; 359(20):2177-2179.
Alvarez CA, Barrientes OJ, Leal AL, Contreras GA, Barrero L, Rincón S, et al. Community-associated methicillin-resistant Staphylococcus aureus, Colombia. Emerg Infect Dis. 2006; 12(12):2000-2001.
Portillo BC, Moreno JE, Yomayusa N, Alvarez CA, Cardozo BEC, Pérez JAE, et al. Molecular epidemiology and characterization of virulence genes of community-acquired and hospitalacquired methicillin-resistant Staphylococcus aureus isolates in Colombia. Int J Infect Dis. 2013; 17(9):e744-749.
Cortes JA, Leal AL, Montañez AM, Buitrago G, Castillo JS, Guzman L, et al. Frequency of microorganisms isolated in patients with bacteremia in intensive care units in Colombia and their resistance profiles. Braz J Infect Dis. 2013; 17(3):346-352.
Castillo JS, Leal AL, Cortes JA, Alvarez CA, Sanchez R, Buitrago G, et al. Mortality among critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia: a multicenter cohort study in Colombia. Rev Panam Salud Pública. 2012; 32(5):343-350.
Cuervo SI, Cortés JA, Sánchez R, Rodríguez JY, Silva E, Tibavizco D, et al. Risk factors for mortality caused by Staphylococcus aureus bacteremia in cancer patients. Enfermedades Infecc Microbiol Clínica. 2010; 28(6):349-354.
Fowler VG Jr, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003; 163(17):2066-2072.